View Article Online View Journal

## Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: F. Ji, M. Lv, W. Yi and C. Cai, *Org. Biomol. Chem.*, 2014, DOI: 10.1039/C4OB00484A.



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/obc

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

### **ARTICLE TYPE**

# One-pot Synthesis of 2-Amino-4(3*H*)-Quinazolinones *via* Ring-opening of Isatoic anhydride and Palladium-catalyzed Oxidative Isocyanide-insertion

Fei Ji,<sup>a, b</sup> Mei-fang Lv,<sup>a, b</sup> Wen-bin Yi,<sup>a</sup> Chun Cai<sup>a</sup>\*

s Received (in XXX, XXX) Xth XXXXXXXX 20XX, Accepted Xth XXXXXXXX 20XX DOI: 10.1039/b000000x

An efficient and practical two-step process has been developed for the synthesis of 2-amino-4(3*H*)quinazolinones *via* ring-opening of isatoic anhydride and palladium-catalyzed oxidative isocyanideinsertion in one-pot. This regioselective procedure could construct a wide range of 2-amino-4(3*H*)-

<sup>10</sup> quinazolinones in moderate to excellent yields. Furthermore, the methodology also had distinct advantages of easily accessible starting materials and operational simplicity.

#### Introduction

The quinazolin-4(*3H*)-one skeleton is an unique unit that exists widely in the medically important products<sup>[1]</sup> For example, 2-<sup>15</sup> amino-4(*3H*)-quinazolinone derivatives have shown high activities as thymidylate synthase inhibitors,<sup>[2a]</sup> cognition enhancement agents,<sup>[2b]</sup> tumor necrosis factor  $\alpha$  inhibitors,<sup>[2e]</sup> dopamine agonists,<sup>[2d]</sup> histamine H4 receptor inverse agonists,<sup>[2e]</sup> anti-inflammatory agents,<sup>[2f]</sup> anti-hypertentive agents,<sup>[2g]</sup> anti-<sup>20</sup> convulsant agents,<sup>[2h]</sup> anti-hyperglycemic agents,<sup>[2i]</sup> and anti-bacterial agents.<sup>[2j]</sup>

A great number of synthetic methods for the generation of 2amino-4(3H)-quinazolinone derivatives have been developed. In general, the synthetic methods can be classified into the following categories: 1) amidation of 2 aminohenzoic acid<sup>[3a]</sup> and its

- <sup>25</sup> categories: 1) amidation of 2-aminobenzoic acid<sup>[3a]</sup> and its derivatives: 2-aminobenzonitrile,<sup>[3b]</sup> 2-aminobenzoate,<sup>[3c]</sup> isatoic anhydride<sup>[3d-3e]</sup> and so on; 2) the tandem aza-wittig reaction of iminophosphorane;<sup>[3f-3h]</sup> 3) the tandem palladium-catalyzed cyclocarbonylation;<sup>[3i-3j]</sup> 4) reactions of nucleophiles: guanidines,
- <sup>30</sup> with ortho-fluorobenzoyl.<sup>[3k]</sup> However, these procedures often suffer from a variety of drawbacks, such as multi-step process, harsh reaction conditions, low yields, hardly accessible starting materials, the utilization of toxic CO, and low molecular diversity, which limit their usages in practical application.
- <sup>35</sup> Therefore, the development of an efficient and step-economic procedure for the synthesis of 2-amino-4(*3H*)-quinazolinones is highly desired.

Isocyanides, a kind of unsaturated molecules similar to carbon monoxide, have emerged as versatile building blocks in the 40 construction of medicinally important molecules and natural products <sup>[4]</sup> Transition-metal catalyzed isocyanide-insertion

products.<sup>[4]</sup> Transition-metal catalyzed isocyanide-insertion reactions to assemble biological N-heterocycles have been previously undervalued and have drawn great attention only in very recent years.<sup>[5]</sup> This methodology offers several distinct <sup>45</sup> advantages such as simple handling, mild condition and wide

substrate scope (variable group at nitrogen) over carbon monoxide.<sup>[5]</sup> In 2012, R. V. A. Orru and co-workers reported a palladium-catalyzed oxidative isocyanide-insertion reaction involving bis-nucleophiles to synthesize 2-amino-4(3H)-<sup>50</sup> guinazolinones.<sup>[6a]</sup> Nevertheless, this protocol was unfortunately not only highly inefficient for the variation at the 3-N position of 2-amino-4(3H)-quinazolinones, but also required multi-step process to synthesize the poor commercial available starting materials. Based on our previous work on the commercial 55 available isatoic anhydrides<sup>[7, 8a]</sup> and isocyanides,<sup>[8]</sup> we have developed a novel and efficient one-pot process for the synthesis of a wide range of 2-amino-4(3H)-quinazolinones via ringopening of isatoic anhydrides and palladium-catalyzed oxidative isocyanide-insertion reaction in a more rapid and flexible manner 60 than the above mentioned conventional methods (Scheme 1). To the best of our knowledge, the previously reported transitionmetal catalyzed isocyanide-insertion reactions are mainly confined to inserting isocyanides to C-H or C-halogen bonds, and this direct insertion of isocvanides into the active N-H bonds in 65 this paper are still relatively rare.<sup>[6]</sup>



Scheme 1 Approaches towards 2-amino-4(3H)-quinazolinone derivatives

#### **Results and Discussion**

To explore this approach, we selected isatoic anhydride (1a), 70 benzyl amine (2a) and *tert*-butyl isocyanide (3a) as the model

Published on 11 June 2014. Downloaded by University of Waterloo on 18/06/2014 06:53:24

substrates to optimize the reaction conditions including solvents, oxidant reagents, and palladium catalysts. Initially, we performed this one-pot process according to the optimized reaction conditions of the pioneering work by R. V. A. Orru.<sup>[6a]</sup> 5 Disappointingly, the desired substituted 2-amino-4(*3H*)-quinazolinone was obtained only in a moderate yield (Table 1, entry 1). To our delight, switching the reaction solvent to toluene could improve the yields obviously (Table 1, entries 2-4).

Subsequently, other oxidant reagents such as copper (II) salts, <sup>10</sup> silver (I) salts, TBHP and  $K_2S_2O_8$  were screened to obtain the better yield (Table 1, entries 5-10). Notably,  $Ag_2CO_3$  was examined to be a more effective oxidant reagent and the yield of **4a** could be improved to 78% yield. Additionally, some commercial palladium catalysts were also screened, but no <sup>15</sup> obvious improvement in yields was observed (Table 1, entries 11 and 12).

Table 1 Optimization of the reaction conditions<sup>a</sup>

Published on 11 June 2014. Downloaded by University of Waterloo on 18/06/2014 06:53:24

(	$ \begin{array}{c} 0 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1$	Solvent, $T^{PC}$	2) [Pd]/Oxidant reac <i>tert</i> -butyl isocyanic One-pot	$\begin{array}{c} \text{gent} & \text{O} \\ \text{de 3a} & \text{N} \\ \text{M} & \text{NH} \\ \text{4a} \\ \end{array}$	×
Entry	Pd catalyst	Oxidant reagent	Solvent	T/°C	Yield <sup>c</sup> (%)
1	Pd(OAc) <sub>2</sub>	$O_2^{b}$	MeTHF	75	42
2	Pd(OAc) <sub>2</sub>	$O_2{}^b$	toluene	100	68
3	Pd(OAc) <sub>2</sub>	$O_2^{b}$	DMF	110	37
4	Pd(OAc) <sub>2</sub>	$O_2^{b}$	MeCN	81	42
5	Pd(OAc) <sub>2</sub>	$K_2S_2O_8$	toluene	100	23
6	Pd(OAc) <sub>2</sub>	Cu(TFA)2 XH2O	toluene	100	72
7	Pd(OAc) <sub>2</sub>	TBHP	toluene	100	25
8	Pd(OAc) <sub>2</sub>	Ag <sub>2</sub> CO <sub>3</sub>	toluene	100	78
9	Pd(OAc) <sub>2</sub>	AgOAc	toluene	100	67
10	Pd(OAc) <sub>2</sub>	Cu(OAc) <sub>2</sub>	toluene	100	37
11	Pd(PPh <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub>	Ag <sub>2</sub> CO <sub>3</sub>	toluene	100	70
12	Pd(amphos)Cl <sub>2</sub>	Ag <sub>2</sub> CO <sub>3</sub>	toluene	100	52

<sup>a</sup> *Reaction conditions:* 1) The reaction was carried out using **1a** (0.50 mmol) and **2a** (0.50 mmol) in solvent (4 ml) at T/°C for 4 h; 2) **3a** (0.75 mmol) was 20 added subsequently in the presence of Pd catalyst (2 mol%) and Oxidant reagent (1.00 mmol) at T/°C for 24 h in one-pot. <sup>b</sup> In O<sub>2</sub> atmosphere (1 atm, balloon). <sup>c</sup> Isolated yields based on **1a**.

Under the optimized reaction conditions, the scope of this reaction was extended to a variety of amines, isocyanides and isatoic anhydrides. The results were summarised in Table 2.

- <sup>25</sup> Generally, various amines, including aryl amines and alkyl amines were well tolerated. Benzyl amines bearing both electronrich and electron-deficient aromatic ring furnished the desired products in high yields (Table 2, 4a-4c). Ortho-substituted benzyl amine would not decrease the reaction rate obviously (Table 2,
- <sup>30</sup> **4d**). In addition, primary alkyl amines and secondary alkyl amines also generated the products in moderate to high yields (Table 2, **4e-4g**). It's worth noticing that the N-boc-amino group of the product **4f** could be further modified to explore the diversification of substituted 2-amino-4(*3H*)-quinazolinones.
- <sup>35</sup> With regard to amines bearing heterocycles, we could also isolate the corresponding products in high yields (Table 2, 4i and 4j). Meanwhile, the reaction was also tolerant of different substituted aryl amines giving the corresponding product, albeit in moderate

yields, due to relatively lower activity of aryl amines (Table 2, 40 4k-4m). Unfortunately, the complex product was formed when 4nitro-aniline was employed in this transformation. This successful utilization of a broad range of amines further efficiently increased the diversification at 3-N position of 2-amino-4(3H)quinazolinones. Next, different isocyanides were also applied to <sup>45</sup> probe the scope of the reaction. When cylcohexyl isocyanide and 1,1,3,3-tetramethylbutyl isocyanide were employed instead of tert-butyl isocyanide, the reaction worked as expected giving corresponding products in high yields (Table 2, 4n and 4o). Finally, we examined the use of different isatoic anhydrides. <sup>50</sup> Noticeably, isatoic anhydrides containing electron-donating ( $R^2$ = 6-Me) and halogen group ( $R^2 = 6$ -F, 6-Cl) reacted efficiently, affording 4 in moderate to high yields (Table 2, 4q, 4s and 4t). However, the electron-withdrawing group on the aromatic ring of isatoic anhydrides (R<sup>2</sup>=6-NO<sub>2</sub>, 6-COOMe) had a negative effect 55 on this reaction, and could not obtain the desired product.

Published on 11 June 2014. Downloaded by University of Waterloo on 18/06/2014 06:53:24

Table 2 Synthesis of 2-amino-4(3H)-quinazolinone derivatives<sup>a, b</sup>



<sup>a</sup> *Reaction conditions:* 1) The reaction was carried out using 1 (0.50 mmol) and 2 (0.50 mmol) in toluene (4 mL) at 100 °C, and the reaction time was determined by TLC (3-8 h); 2) 3 (0.75 mmol) was added subsequently in the presence of Pd catalyst (2 mol%) and Ag<sub>2</sub>CO<sub>3</sub> (1.00 mmol) at 100 °C for 24 h in one-pot. <sup>b</sup> Isolated yields on 1.

<sup>5</sup> To further expand the scope of 2-amino-4(*3H*)-quinazolinone, we also tried to access the unsubstituted 2-amino-4(*3H*)quinazolinone by the acid-promoted dealkylation sequence (Scheme 2). Addition of TFA to 2-(*tert*-butylamino)-quinazolin-4(*3H*)-one and subsequent heating under reflux finally furnished <sup>10</sup> unsubstituted 2-amino-4(*3H*)-quinazolinone in a moderate yield. This process provided a valuable alternative to the use of highly toxic cyanogens bromide,<sup>[6a]</sup> especially since *tert*-butyl isocyanide was an easily accessible and convertible isocyanide.



15 Scheme 2 Synthesis of unsubstituted 2-amino-4(3H)-quinazolinone

The structures of 2-amino-4(*3H*)-quinazolinones **4a-4u** were fully characterized by Mass spectrometry, <sup>1</sup>H NMR, <sup>13</sup>C NMR spectroscopy and elemental analysis. Moreover, the structure of **4j** was also confirmed by single-crystal X-ray analysis (Figure 1).

<sup>20</sup> Based on the well-established chemistry of isocyanide,<sup>[6]</sup> the proposed mechanism was depicted in Scheme 3. Initially, the ring-opening reaction of isatoic anhydride 1 with amine 2



Figure 1 single-crystal X-ray analysis of 4j

<sup>25</sup> generates the bis-nucleophile II. Catalysis I reacts with the bisnucleophile II to form the intermediate III. Then, isocaynideinsertion reaction occurs, resulting in the species IV. Species IV subsequently undergoes reductive elimination to afford the product 4. Pd(0) species VI is stabilized by coordination of <sup>30</sup> multiple isocyanides and then oxidized by silver carbonate to regenerate the catalyst. The occurrence of silver and carbon dioxide in the experiment also further confirmed this mechanism.



Scheme 3 Possible mechanism of this two-step reaction

Considering the fact that the discovery of new molecular scaffolds is essential to meet the temporary demands for improved materials and pharmaceuticals, we used this method to synthesize 2-amino-3-hydroxyquinazolin-4(*3H*)-ones (Scheme 4). Its analogous bicyclic-pyrimidinones have been proved to be effective HCV NS5B active site inhibitors.<sup>[9]</sup> The ring-opening reaction of isatoic anhydride with O-benzyl hydroxylamine and subsequent palladium-catalyzed oxdative isocyanide-insertion reaction in one-pot proceeded smoothly in the presence of Pd(OAc)<sub>2</sub> and Ag<sub>2</sub>CO<sub>3</sub> to afford 3-(benzyloxy)-2-aminoquinazolin-4(*3H*)-one **4v** in 65% yield. The following hydroxyquinazolin-4(*3H*)-ones **4w** in a high yield to further increase the variation at the 3-N position of 2-amino-4(*3H*)quinazolinones.



Scheme 4 Synthesis of 2-amino-3-hydroxyquinazolin-4(3H)-ones

#### Conclusions

Published on 11 June 2014. Downloaded by University of Waterloo on 18/06/2014 06:53:24

In counclusion, we have developed an efficient and practical onepot process for the synthesis of 2-amino-4(*3H*)-quinazolinones <sup>25</sup> via ring-opening of isatoic anhydride and palladium-catalyzed oxidative isocyanide-insertion. This regioselective methodology was successful with a range of amines, isatoic anhydrides and isocyanides, and could afford the desired heterocycles in moderate and high yields. This process also had distinct

#### **Experimental section**

Unless otherwise stated, all commercial reagents were used as received. All melting points were uncorrected. Mass spectra were recorded on Shimadzu LCMS-2020. <sup>1</sup>H and <sup>13</sup>C NMR spectra <sup>40</sup> were recorded at 500 MHz and 125 MHz in CDCl<sub>3</sub>, and chemical shifts were reported in ppm from internal TMS ( $\delta$ ). Elemental analyses were performed on a Yanagimoto MT3CHN recorder.

#### General procedure for the synthesis of 2-substituted-amino-

45 4(3H)-quinazolinones 4a-4t: To a solution of isatoic anhydride 1 (0.50 mmol) in toluene (4 mL) was added amine 2 (0.50 mmol). The mixture was stirred at 100 °C in a sealed tube for 3-8 h (according to the determination of TLC). Upon the completion of the reaction, isocyanide 3 (0.75 mmol), Pd(OAc)<sub>2</sub> (2 mol%) and 50 Ag<sub>2</sub>CO<sub>3</sub> (1.00 mmol) was successively added. The mixture was then kept stirring at 100 °C for another 24 h. After that, the product was then concentrated under vacuum and the resulting residue was purified by column chromatography.

**3-benzyl-2-**(*tert*-butylamino)quinazolin-4(*3H*)-one 4a: white solid, 138-140 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.35 (s, 9H), 4.35 (s, 1H), 5.33 (s, 2H), 7.22 (t, *J*=7.0 Hz, 1H), 7.28-7.30 (m, 2H), 7.34-7.36 (m, 1H), 7.37-7.41 (m, 3H), 7.59-7.61 (m, 1H), 8.21 (d, *J*=1.3 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 27.83, 43.89, 51.59, 115.97, 121.44, 124.28, 125.71, 126.27, 127.25, 60 128.33, 133.19, 134.49, 147.45, 148.07, 162.29; Ms (ESI) *m/z*: 308 [M+H]; Anal. Calcd for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O: C,74.24; H, 6.89; N, 13.67; found C, 74.39; H, 6.98; N, 13.61.

#### 2-(tert-butylamino)-3-(4-methylbenzyl)quinazolin-4(3H)-one

<sup>65</sup> **4b**: white solid, 141-143 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.36 (s, 9H), 2.37 (s, 3H), 4.41 (s, 1H), 5.28 (s, 2H), 7.17-7.19 (m, 5H), 7.40 (d, *J*=8.0 Hz, 1H), 7.59-7.60 (m, 1H), 8.20-8.22 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 20.16, 27.85, 43.76, 51.56, 115.99, 121.39, 124.25, 125.70, 126.25, 128.98, 131.34, 133.16, <sup>70</sup> 137.05, 147.57, 148.07, 162.34; Ms (ESI) *m/z*: 322 [M+H]; Anal. Calcd for C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O: C,74.74; H, 7.21; N, 13.07; found C, 74.62; H, 7.12; N, 13.12.

#### 2-(tert-butylamino)-3-(4-fluorobenzyl)quinazolin-4(3H)-one

- <sup>75</sup> 4c: white solid, 158-160 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.36 (s, 9H), 4.26 (s, 1H), 5.28 (s, 2H), 7.08 (t, *J*=8.5 Hz, 2H), 7.20 (t, *J*=7.0 Hz, 1H), 7.25-7.28 (m, 2H), 7.39 (d, *J*=8.0 Hz, 1H), 7.59-7.60 (m, 1H), 8.18-8.20 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 27.87, 43.25, 51.66, 115.23, 115.40, 115.91, 121.57, 124. 32, 80 126.23, 127.43, 127.49, 130.26, 133.31, 147.22, 147.99, 160.55, 162.25, 162.52; Ms (ESI) *m/z*: 326 [M+H]; Anal. Calcd for C<sub>19</sub>H<sub>20</sub>FN<sub>3</sub>O: C,70.13; H, 6.20; N, 12.91; found C, 70.27; H, 6.27; N, 12.82.
- <sup>85</sup> 2-(*tert*-butylamino)-3-(2-fluorobenzyl)quinazolin-4(*3H*)-one 4d: white solid, 148-150 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.43 (s, 9H), 4.61 (s, 1H), 5.34 (s, 2H), 7.11-7.20 (m, 3H), 7.29-7.31 (m, 1H), 7.37-7.39 (m, 2H), 7.58-7.59 (m, 1H), 8.17-8.19 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 27.86, 36.33, 51.72, 114.23,

Published on 11 June 2014. Downloaded by University of Waterloo on 18/06/2014 06:53:24

114.40, 115.87, 121.40, 121.55, 124.23, 126.19, 128.95, 133.26, 146.77, 148.02, 158.28, 160.22, 162.41; Ms (ESI) m/z: 326 [M+H]; Anal. Calcd for C<sub>19</sub>H<sub>20</sub>FN<sub>3</sub>O: C,70.13; H, 6.20; N, 12.91; found C, 70.02; H, 6.14; N, 12.99.

**3-butyl-2-**(*tert*-butylamino)quinazolin-4(*3H*)-one 4e: white solid, 145-147 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.00 (t, *J*=7.4 Hz, 3H), 1.44-1.48 (m, 2H), 1.55 (s, 9H), 1.66-1.72 (m, 2H), 4.00 (t, *J*=7.8 Hz, 2H), 4.37 (s, 1H), 7.13 (t, *J*= 8.0 Hz, 1H), 7.36 (d, <sup>10</sup> *J*=8.2 Hz, 1H), 7.53-7.57 (m, 1H), 8.09-8.11 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 12.75, 19.28, 28.21, 28.77, 39.94, 51.57, 116.11, 121.28, 124.11, 125.93, 132.94, 146.93, 147.80, 161.85; Ms (ESI) *m/z*: 274 [M+H]; Anal. Calcd for C<sub>16</sub>H<sub>23</sub>N<sub>3</sub>O: C,70.30; H, 8.48; N, 15.37; found C, 70.17; H, 8.41; N, 15.45.

*tert*-butyl-2-(2-(*tert*-butylamino)-4-oxoquinazolin-3(*4H*)-yl) ethylcarbamate 4f: white solid, 204 -206 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.46 (s, 9H), 1.59 (s, 9H), 3.28-3.32 (m, 2H), 4.07-4.10 (m, 2H), 5.23 (s, 1H), 6.28 (s, 1H), 7.10 (t, *J*=7.5 Hz, 20 1H), 7.37-7.38 (m, 1H), 7.52-7.55 (m, 1H), 8.04-8.06 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 27.34, 28.09, 37.54, 39.27, 52.02, 79.40, 115.50, 121.00, 124.09, 125.67, 133.12, 147.51, 148.18, 156.01, 162.22; Ms (ESI) *m/z*: 361 [M+H]; Anal. Calcd for C<sub>19</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>: C, 63.31; H, 7.83; N, 15.54; found C, 63.23; H, 25 7.75; N, 15.61.

**2-**(*tert*-butylamino)-3-isopropylquinazolin-4(*3H*)-one 4g: white solid, 118-120°C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.52 (s, 3H), 1.53 (s, 3H), 1.54 (s, 9H), 4.47 (s, 1H), 5.59 (s, 1H), 7.08-7.12 <sup>30</sup> (m, 1H), 7.31 (d, *J*=8.2 Hz, 1H), 7.50-7.54 (m, 1H), 8.06-8.08 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 19.40, 28.32, 42.47, 51.68, 116.50, 121.18, 123.80, 126.07, 132.91, 147.11, 147.68, 162.35; Ms (ESI) *m/z*: 260 [M+H]; Anal. Calcd for C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O: C, 69.47; H, 8.16; N, 16.20; found C, 69.34; H, 8.21; N, 16.27.

<sup>35</sup> **2-(cyclohexylamino)-3-isopropylquinazolin-4(3H)-one** 4h: white solid, 129-131°C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.26-1.32 (m, 3H), 1.45-1.51 (m, 2H), 1.54 (s, 3H), 1.56 (s, 3H), 1.65-1.68 (m, 1H), 1.73-1.75 (m, 2H), 2.12-2.13 (m, 2H), 4.17 (s, 1H), 4.53 <sup>40</sup> (s, 1H), 5.54 (s, 1H), 7.12 (d, *J*=7.5 Hz, 1H), 7.38 (s, 1H), 7.54 (t, *J*=7.5 Hz, 1H), 8.07 (d, *J*= 8.0 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 19.32, 23.70, 24.74, 32.11, 42.93, 49.28, 116.36, 121.40, 123.24, 126.17, 133.18, 147.90, 162.03; Ms (ESI) *m/z*: 286 [M+H]; Anal. Calcd for C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>O: C, 71.55; H, 8.12; N, <sup>45</sup> 14.72; found C, 71.42; H, 8.17; N, 14.81.

**2-(***tert***-butylamino)-3-(furan-2-ylmethyl)quinazolin-4(***3H***)-one <b>4i:** white solid, 148-150 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.42 (s, 9H), 5.01 (s, 1H), 5.14 (s, 2H), 6.27-6.28 (m, 1H), 6.37 (d, <sup>50</sup> *J*=3.2 Hz, 1H), 7.02-7.05 (m, 1H), 7.27-7.28 (m, 2H), 7.44-7.45 (m, 1H), 8.00-8.02 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 28.05, 36.89, 51.77, 108.78, 110.18, 116.00, 121.48, 124.19, 126.04, 133.21, 141.41, 147.35, 147.73, 148.41, 161.70; Ms (ESI) *m/z*: 298 [M+H]; Anal. Calcd for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>: C, 68.67; H, <sup>55</sup> 6.44; N, 14.13; found C, 68.55; H, 6.51; N, 14.18.

**2-**(*tert*-butylamino)-3-((5-methylfuran-2-yl)methyl)quinazolin -4(*3H*)-one 4j: white solid, 130-132 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.55 (s, 9H), 2.29 (s, 3H), 5.18 (s, 2H), 5.30 (s, 1H), 60 5.96 (t, *J*=2.2 Hz, 1H), 6.35 (d, *J*=3.1 Hz, 1H), 7.16 (t, *J*=7.1 Hz, 1H), 7.38-7.40 (m, 1H), 7.54-7.58 (m, 1H), 8.11-8.13 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 12.49, 28.09, 36.92, 51.78, 105.98, 109.75, 116.08, 121.39, 124.13, 126.04, 133.11, 146.57, 147.56, 147.72, 151.18, 161.65; Ms (ESI) *m/z*: 312 [M+H]; Anal.  $^{65}$  Calcd for  $C_{18}H_{21}N_3O_2{:}$  C, 69.43; H, 6.80; N, 13.49; found C, 69.34; H, 6.72; N, 13.56.

**2-**(*tert*-butylamino)-3-p-tolylquinazolin-4(*3H*)-one 4k: white solid, 148-150 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.40 (s, 9H), 70 2.44 (s, 3H), 3.99 (s, 1H), 7.12-7.16 (m, 3H), 7.37 (d, *J*=8.0 Hz, 2H), 7.42 (d, *J*=8.0 Hz, 1H), 7.57-7.59 (m, 1H), 8.10-8.12 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 20.35, 28.04, 51.48, 116.58, 121.33, 124.15, 126.13, 127.51, 130.21, 131.41, 133.34, 138.84, 147.30, 148.22, 161.87; Ms (ESI) *m/z*: 308 [M+H]; Anal. Calcd 75 for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O: C, 74.24; H, 6.89; N, 13.67; found C, 74.12; H, 6.80; N, 13.76.

2-(*tert*-butylamino)-3-(4-chlorophenyl)quinazolin-4(*3H*)-one

**41:** white solid, 170-172 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.41 <sup>80</sup> (s, 9H), 3.84 (s, 1H), 7.16 (t, *J*=1.0 Hz, 1H), 7.23-7.25 (m, 2H), 7.33 (d, *J*=8.0 Hz, 1H), 7.55-7.56 (m, 2H), 7.56-7.60 (m, 1H), 8.09-8.11 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 28.03, 51.71, 116.38, 121.60, 124.30, 126.10, 129.36, 129.85, 132.69, 133.61, 134.85, 146.61, 148.17, 161.72; Ms (ESI) *m/z*: 328 [M+H]; Anal. <sup>85</sup> Calcd for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O: C, 65.95; H, 5.53; N, 12.82; found C, 65.82; H, 5.59; N, 12.75.

**2-**(*tert*-butylamino)-3-phenylquinazolin-4(*3H*)-one 4m: white solid, 120-122 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.39 (s, 9H), <sup>90</sup> 3.91 (s, 1H), 7.15 (t, *J*=1.0 Hz, 1H), 7.28-7.30 (m, 2H), 7.44 (d, *J*=8.0 Hz, 1H), 7.53-7.54 (m, 1H), 7.57-7.60 (m, 3H), 8.10-8.11 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 28.00, 51.51, 116.56, 121.41, 124.22, 126.12, 127.87, 128.75, 129.56, 133.44, 134.22, 147.08, 148.27, 161.81; Ms (ESI) *m/z*: 294 [M+H]; Anal. Calcd <sup>95</sup> for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O: C, 73.69; H, 6.53; N, 14.32; found C, 73.76; H, 6.59; N, 14.21.

**3-benzyl-2-(2,4,4-trimethylpentan-2-ylamino)-quinazolin-4(3H)-one 4n**: white solid, 124-126 °C; <sup>1</sup>H NMR (500 MHz, 100 CDCl<sub>3</sub>) δ: 0.67 (s, 9H), 1.28 (s, 6H), 1.73 (s, 2H), 4.26 (s, 1H), 5.20 (s, 2H), 7.08 (t, *J*=7.0 Hz, 1H), 7.16-7.18 (m, 2H), 7.22 (d, *J*=7.0 Hz, 1H), 7.25-7.31 (m, 3H), 7.47-7.49 (m, 1H), 8.08-8.10 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 28.62, 30.29, 30.43, 44.05, 49.61, 55.43, 115.84, 121.39, 124.24, 125.88, 126.24, 105 127.36, 128.37, 133.23, 134.39, 147.26, 147.93, 162.33; Ms (ESI) *m/z*: 364 [M+H]; Anal. Calcd for C<sub>23</sub>H<sub>29</sub>N<sub>3</sub>O: C, 76.00; H, 8.04; N, 11.56; found C, 76.19; H, 8.11; N, 11.49.

**3-benzyl-2-(cyclohexylamino)quinazolin-4(3H)-one 40:** white <sup>110</sup> solid, 144-146 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.00-1.06 (m, 2H), 1.13-1.18 (m, 1H), 1.32-1.39 (m, 2H), 1.48-1.54 (m, 3H), 1.83-1.86 (m, 2H), 3.96-3.98 (m, 1H), 4.35 (s, 1H), 5.34 (s, 2H), 7.20 (m, 1H), 7.27-7.39 (m, 6H), 7.58-7.60 (m, 1H), 8.19-8.20 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 23.20, 24.58, 31.52, 115 43.61, 48.74, 115.92, 121.43, 123.97, 125.62, 126.36, 127.26, 128.38, 133.35, 134.34, 148.45, 162.17; Ms (ESI) *m/z*: 334 [M+H]; Anal. Calcd for C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O: C, 75.65; H, 6.95; N, 12.60; found C, 75.52; H, 6.87; N, 12.69.

#### 120 **3-benzyl-6-chloro-2-(2,4,4-trimethylpentan-2-ylamino)**

**quinazolin-4(3H)-one 4p:** white solid, 130-132 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 0.75 (s, 9H), 1.37 (s, 6H), 1.80 (s, 2H), 4.40 (s, 1H), 5.27 (s, 2H), 7.25-7.26 (m, 2H), 7.32-7.38 (m, 4H), 7.48-7.50 (m, 1H), 8.13-8.14 (m, 1H); <sup>13</sup>C NMR (125 MHz, 125 CDCl<sub>3</sub>)  $\delta$ : 28.58, 30.26, 30.41, 44.20, 49.59, 55.56, 116.68, 125.40, 125.86, 126.55, 127.49, 128.43, 133.53, 134.04, 146.51, 147.41, 161.36; Ms (ESI) *m/z*: 398 [M+H]; Anal. Calcd for C<sub>23</sub>H<sub>28</sub>ClN<sub>3</sub>O: C, 69.42; H, 7.09; N, 10.56; found C, 69.30; H, 7.18; N, 10.51.

This journal is © The Royal Society of Chemistry [year]

**3-benzyl-2-**(*tert*-butylamino)-6-chloroquinazolin-4(*3H*)-one 4q: white solid, 152-154 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.30 (s, 9H), 4.38 (s. 1H), 5.28 (s, 2H), 7.24-7.25 (m, 2H), 7.30-7.38 5 (m, 4H), 7.48-7.50 (m, 1H), 8.13 (d, *J*=2.5 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 27.78, 44.04, 51.75, 116.76, 125.41, 125.68, 125.94, 126.59, 127.41, 128.42, 133.52, 134.10, 146.64, 147.57, 161.34; Ms (ESI) *m/z*: 342 [M+H]; Anal. Calcd for C<sub>19</sub>H<sub>20</sub>ClN<sub>3</sub>O: C, 66.76; H, 5.90; N, 12.29; found C, 66.88; H, <sup>10</sup> 5.81; N, 12.23.

**3-benzyl-6-chloro-2-(cyclohexylamino)quinazolin-4(***3H***)-one <b>4r:** white solid, 174-176 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.00-1.06 (m, 2H), 1.14-1.18 (m, 1H), 1.31-1.38 (m, 2H), 1.47-1.55 <sup>15</sup> (m, 3H), 1.81-1.84 (m, 2H), 3.93-3.94 (m, 1H), 4.39 (s, 1H), 5.31 (s, 2H), 7.26-7.27 (m, 2H), 7.30-7.39 (m, 4H), 7.50-7.52 (m, 1H), 8.14 (d, *J*=2.5 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 23.17, 24.52, 31.48, 43.78, 48.89, 116.72, 125.59, 126.63, 127.42, 128.46, 133.67, 133.96, 147.02, 148.25, 161.17; Ms (ESI) *m/z*: <sup>20</sup> 368 [M+H]; Anal. Calcd for C<sub>21</sub>H<sub>22</sub>ClN<sub>3</sub>O: C, 68.56; H, 6.03; N, 11.42; found C, 68.68; H, 6.09; N, 11.31.

**3-benzyl-2-(***tert***-butylamino)-6-fluoroquinazolin-4**(*3H***)-one 4s:** white solid, 130-132°C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.32 (s, <sup>25</sup> 9H), 4.32 (s, 1H), 5.30 (s, 2H), 7.26 -7.27(m, 1H), 7.32-7.39 (m, 6H), 7.81-7.83 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 27.79, 44.06, 51.61, 110.56, 110.75, 116.41, 121.66, 121.85, 125.69, 126.21, 126.27, 127.35, 128.38, 134.22, 144.70, 146.97, 156.36, 158.29, 161.65; Ms (ESI) *m/z*: 326 [M+H]; Anal. Calcd for <sup>30</sup> C<sub>19</sub>H<sub>20</sub>FN<sub>3</sub>O: C, 70.13; H, 6.20; N, 12.91; found C, 70.23; H, 6.15; N, 12.84.

#### 3-benzyl-2-(tert-butylamino)-6-methylquinazolin-4(3H)-one

**4t:** white solid, 152-154°C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 1.31 <sup>35</sup> (s, 9H), 2.42 (s, 3H), 4.26 (s, 1H), 5.30 (s, 2H), 7.25-7.27 (m, 2H), 7.29-7.43 (m, 5H), 7.98 (s, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ: 20.95, 28.79, 44.83, 52.46, 116.55, 125.08, 126.50, 126.65, 128.16, 129.25, 132.07, 135.53, 135.69, 146.88, 147.93, 163.25; Ms (ESI) *m/z*: 322 [M+H]; Anal. Calcd for C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O: <sup>40</sup> C, 74.74; H, 7.21; N, 13.07; found C, 74.63; H, 7.15; N, 13.14.

General procedure for the synthesis of 2-unsubstitutedamino-4(*3H*)-quinazolinones 4u: The solution of 2-(*tert*butylamino)-3-(4-methylbenzyl)quinazolin-4(*3H*)-one 4b (0.30 <sup>45</sup> mmol) in TFA (4 mL) was stirred under reflux in a sealed tube overnight. Subsequently, the mixture was basified with aq. NaOH (3 M). The product was extracted with EtOAc and dried (Na<sub>2</sub>SO<sub>4</sub>), which was then purified by column chromatography to give 2-unsubstituted-amino-4(*3H*)-quinazolinones 4u.

- **2-amino-3-(4-methylbenzyl)quinazolin-4(***3H***)-one <b>4u**: white solid, 167-169 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ: 2.34 (s, 3H), 5.33 (s, 2H), 7.16-7.20 (m, 4H), 7.26-7.29 (m, 1H), 7.34 (d, *J*=8.0 Hz, 1H), 7.64 (t, *J*=7.0 Hz, 1H), 8.21 (d, *J*=8.0 Hz, 1H); <sup>13</sup>C <sup>55</sup> NMR (125 MHz, CDCl<sub>3</sub>) δ: 20.08, 44.26, 116.32, 122.42, 123.11, 125.64, 126.56, 129.12, 130.79, 133.71, 137.27, 147.30, 150.45, 161.61; Ms (ESI) *m/z*: 266 [M+H]; Anal. Calcd for C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O: C, 72.43; H, 5.70; N, 15.84; found C, 72.56; H, 5.62; N, 15.71.
- <sup>60</sup> General procedure for the synthesis of 2-amino-3hydroxyquinazolin-4(*3H*)-ones 4w: To a solution of isatoic anhydride (0.50 mmol) in toluene (4 mL) was added *O*phenylhydroxylamine (0.50 mmol). The mixture was stirred at 100 °C in a sealed tube for 4 h. Upon the completion of the

- <sup>65</sup> reaction, *tert*-butylisocyanide (0.75 mmol), Pd(OAc)<sub>2</sub> (2 mol%) and Ag<sub>2</sub>CO<sub>3</sub> (1.00 mmol) was successively added and the mixture was stirred at 100 °C for another 24 h. The product was then concentrated under vacuum and the resulting residue was purified by column chromatography to give 3-(benzyloxy)-2-(*tert*-70 butylamino)quinazolin-4(*3H*)-one **4v**. Secondly, Pd/C 10% was added to the solution of **4v** in ethanol (4 mL) and the mixture was hydrogenated at the room temperature at 40 psi for 6 h. After that, the reaction mixture was passed through Celite, followed by
- evaporation to afford the crude product, which was purified by 75 column chromatography to yield 2-(*tert*-butylamino)-3hydroxyquinazolin-4(*3H*)-one **4w**.

**3-(benzyloxy)-2-(***tert***-butylamino)quinazolin-4(***3H***)-one 4v:** white solid, 120-122 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.32 (s, 9 H), 5.19 (s, 1H), 5.26 (s, 2H), 7.16 (t, *J*=7.0 Hz, 1H), 7.36 (d, *J*=8.0 Hz, 1H), 7.41-7.44 (m, 5H), 7.55 (t, *J*=7.0 Hz, 1H), 8.12-8.13 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 27.65, 50.82, 77.45, 117.63, 121.18, 124.33, 125.63, 128.12, 128.79, 129.29, 132.81, 133.16, 145.50, 147.04, 157.58; Ms (ESI) *m/z*: 324 ss [M+H]; Anal. Calcd for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>: C, 70.57; H, 6.55; N, 12.99; found C, 70.63; H, 6.67; N, 12.91.

**2-***(tert*-butylamino)-3-hydroxyquinazolin-4(*3H*)-one 4w: white solid, 174-176 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.51 (s, 9H), <sup>90</sup> 5.80 (s, 1H), 7.11-7.14 (m, 1H), 7.39 (d, *J*=8.2 Hz, 1H), 7.55-7.58 (m, 1H), 8.03-8.05 (m, 1H), 11.37 (s, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 28.12, 50.96, 115.61, 121.27, 123.68, 125.15, 133.68, 148.21, 164.44; Ms (ESI) *m/z*: 234 [M+H]; Anal. Calcd for C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>: C, 61.79; H, 6.48; N, 18.01; found C, 61.86; H, <sup>95</sup> 6.39; N, 18.07.

Crystallographic data for the product **4j** has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC 966928. These data can be obtained free of <sup>100</sup> charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk /data\_request/cif.

#### Acknowledgements

We thank financial support from Jiangsu Creative Research Funding for Graduate Students (CXZZ13\_02) and Jiangsu <sup>105</sup> Natural Science Foundation (BK20131346)

#### Notes and references

<sup>*a*</sup> Chemical Engineering College, Nanjing University of Science and Technology, Nanjing, China. Fax: (+86)-25-8431-5030; E-mail: <u>c.cai@mail.njust.edu.cn</u>.

<sup>110</sup> <sup>*b*</sup> Fei  $\overline{Ji}$  and Mei-fang Lv contributed equally to this paper.

- <sup>†</sup> Electronic Supplementary Information (ESI) available: Copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra (**4a-4u**). Crystallographic data for **4j**: CCDC 966928. See DOI: 10.1039/b00000x/
- a) D. J. Connolly, D. Cusack, T. P. O'Sullivan and P. J. Guiry, *Tetrahedron*, 2005, **61**, 10153; b) M. A. H. Ismail, S. Barker, D. A. Abou El Ella, K. A. M. Abouzid, R. A. Toubar and M. H. Todd, *J. Med. Chem.*, 2006, **49**, 1526; c) D. W. Fry, A. J. Kraker, A. McMichael, L. A. Ambroso, J. M. Nelson, W. R. Leopold, R. W. Connors and A. L. Bridges, *Science*, 1994, **265**, 1093.
- <sup>120</sup> 2 a) D. J. McNamara, E. M. Berman, D. W. Fry and L. M. Werbel, *J. Med. Chem.*, 1990, **33**, 2045; b) J. I. Levin, W. J. Fanshawe, J. W. Epstein, B. Beer, R. T. Bartus and R. L. Dean, *Bioorg. Med. Chem. Lett.*, 1992, **2**, 349; c) Q. Chao, L. Deng, H. Shih, L. M. Leoni, D. Genini, D.

Published on 11 June 2014. Downloaded by University of Waterloo on 18/06/2014 06:53:24

A. Carson and H. B. Cottam, J. Med. Chem., 1999, 42, 3860; d) J. A. Grosso, E. D. Nichols, J. D. Kohli and D. Glock, J. Med. Chem., 1982, 25, 703; e) R. A. Smits, I. J. P. de Esch, O. P. Zuiderveld, J. Broeker, K. Sansuk, E. Guaita, G. Coruzzi, M. Adami, E. Haaksma and R. Leurs, J.

- <sup>5</sup> Med. Chem., 2008, **51**, 7855; f) V. Alagarsamy, K. Dhanabal, P. Parthiban, G. Anjana, G. Deepa, B. Murugesan, S. Rajkumar and A. J. Beev, J. Pharm. Pharmacol., 2007, **59**, 669; g) J. W. Chern, P. L. Tao, K. C. Wang, A. Gutcait, S. W. Liu, M. H. Yen, S. L. Chien and J. K. Rong, J. Med. Chem., 1998, **41**, 3128; h) M. Zappala, S. Grasso, N.
- Micale, G. Zuccala, F. S. Menniti, G. Ferreri, G. D. Sarroc and C. D. Micheli, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 4427; i) V. J. Ram, Farhanullah, B. K. Tripathi and A. K. Srivastava, *Bioorg. Med. Chem.*, 2003, **11**, 2439; j) W. Pendergast, J. V. Johnson, S. H. Dickerson, I. K. Dev, D. S. Duch, R. Ferone, W. R. Hall, J. Humphreys, J. M. Kelly and D. C. Wilson, *J. Med. Chem.*, 1993, **36**, 2279.
- 3 a) F. Somers, R. Ouedraogo, M. H. Antoine, P. de Tullio, B. Becker, J. Fontaine, J. Damas, L. Dupont, B. Rigo, J. Delarge, P. Lebrun and B. Pirotte, J. Med. Chem., 2001, 44, 2575; b) L. J. Wilson, Org. Lett., 2001, 3, 585; c) H. J. Hess, T. H. Cronin and A. Scriabine, J. Med.
- Chem., 1968, 11, 130; d) R. Y. Yang and A. Kaplan, Tetrahedron Lett., 2000, 41, 7005; e) A. Gopalsamy and H. Yang, J. Comb. Chem., 2000, 2, 378; f) M. W. Ding, G. P. Zeng and T. J. Wu, Synth. Commun., 2000, 30, 1599; (g) S. Makino, T. Okuzumi, T. Tsuji and E. Nakanishi, J. Comb. Chem., 2003, 5, 756; h) W. Zhang, J. P. Mayer, S. E. Hall and J.
- A. Weigel, J. Comb. Chem., 2001, **3**, 255; i) C. Larksarp and H. Alper, J. Org. Chem., 2000, **65**, 2773; j) F. Zeng and H. Alper, Org. Lett., 2010, **12**, 1188; k) M. J. Fray, J. P. Mathias, C. L. Nichols, Y. M. Po-Ba and H. Snow, Tetrahedron Lett., 2006, **47**, 6365.
- For selected examples, see: a) A. V. Lygin and A. de Meijere, Angew.
   Chem. Int. Ed., 2010, 49, 9094; b) T. Yue, M. X. Wang, D. X. Wang, G. Masson and J. Zhu, J. Org. Chem., 2009, 74, 8396; c) H. Mihara, Y. Xu, N. E. Shepherd, S. Matsunaga and M. Shibasaki, J. Am. Chem. Soc., 2009, 131, 8384; d) R. Scheffelaar, M. Paravidino, D. Muilwijk, M. Lutz, A. L. Spek, F. J. J. de Kanter, R. V. A. Orru and E. Ruijter, Org. 35 Lett., 2009, 11, 125.
- <sup>55</sup> For selected recent reviews on isocyanide-insertion reaction, see: a) T.
   <sup>56</sup> Vlaar, E. Ruijter, B. U. W. Maes, and R. V. A. Orru, *Angew. Chem. Int. Ed.*, 2013, **52**, 7084; b) S. Lang, *Chem. Soc. Rev.*, 2013, **42**, 4867; c) G.
   Qiu, Q. Ding and J. Wu, *Chem. Soc. Rev.*, 2013, **42**, 5257.
- <sup>40</sup> 6 a) T. Vlaar, R. C. Cioc, P. Mampuys, B. U. M. Maes, R. V. A. Orru and E. Ruijter, *Angew. Chem. Int. Ed.*, 2012, **51**, 13058; b) T. H. Zhu, S.Y. Wang, G. N. Wang and S. J. Ji, *Chem. Eur. J.*, 2013, **19**, 5850; c) B. Liu, M. Yi, H. Gao, W. Wu and H. Jiang, *J. Org. Chem.*, 2013, **78**, 3009; d) T. H. Zhu, X. Zhu, X. P. Xu, T. Chen and S. J. Ji, *Tetrahedron* <sup>45</sup> Lett., 2011, **52**, 2771.
- 7 L. Y. Zeng, W. B. Yi and C. Cai, Eur. J. Org. Chem., 2012, 559.
- 8 a) F. Ji, M. F. Lv, W. B. Yi and C. Cai, *Synthesis*, 2013, 45, 1965; b) F. Ji, M. F. Lv, W. B. Yi and C. Cai, *Adv. Synth. Catal.*, 2013, 355, 3401.
  9 R. R. Deore, G. S. Chen, P. T. Chang, T. R. Chern, S. Y. Lai, M. H.
- Chuang, J. H. Lin, F. L. Kung, C. S. Chen, C. T. Chiou and J. W. Chern, *ChemMedChem*, 2012, 7, 850.